FDA Extends Review of Zevra's Arimoclomol by Three Months
By Colin Kellaher
The U.S. Food and Drug Administration has extended by three months its review of an application from Zevra Therapeutics seeking approval of its lead product candidate arimoclomol for Niemann-Pick disease type C, a rare neurodegenerative disorder.
Zevra on Monday said the FDA needs more time to review additional analyses the Celebration, Fla., company provided in responses to recent information requests by the agency.
Zevra said the FDA set a new target action date of Sept. 21 for the application, adding that the agency confirmed that it plans to hold an advisory committee meeting that has yet to be scheduled.
Denmark's Orphazyme, which previously owned the arimoclomol program, initially filed for FDA approval of the drug in September 2020, but the agency rejected the application in June 2021.
Zevra, which acquired all of the assets and operations of Orphazyme related to arimoclomol in May 2022, resubmitted a new drug application for arimoclomol late last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 04, 2024 08:22 ET (13:22 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks